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Glycogensynthasekinase-3(GSK-3)uniquepositioninmodulatingthefunctionofadiverseseriesofproteinsincombinationwith
its associationwith a wide variety of human disorders has attracted signiﬁcantattention to the protein both as a therapeutic target
andasameanstounderstandthemolecularbasisofthesedisorders.GSK-3isubiquitously expressed and, unusually, constitutively
active in resting, unstimulated cells. In mammals, GSK-3α and β are each expressed widely at both the RNA and protein levels
although some tissues show preferential levels of some of the two proteins. Neither gene appears to be acutely regulated at the
transcriptional level, whereas the proteins are controlled posttranslationally, largely through protein-protein interactions or by
posttranslationalregulation. Control ofGSK-3activity thus occurs by complex mechanismsthat are each dependent upon speciﬁc
signalling pathways. Furthermore, GSK-3 appears to be a cellular nexus, integrating several signalling systems, including several
secondmessengers anda wide selection ofcellular stimulants.This paper willfocus on the diﬀerent waysto control GSK-3 activity
(phosphorylation,protein complex formation,truncation, subcellular localization,etc.), the main signallingpathways involved in
its control, and its pathological deregulation.
1.Introduction
Glycogen synthase kinase-3 (GSK-3) is a CMGC serine/
threonine protein kinase initially described as one of the
kinases that phosphorylates and inhibits glycogen synthase
[1]. It is now widely accepted though that GSK-3 plays an
important role in various essential physiological processes,
such as development, cell cycle, or apoptosis [2]. Apart from
glycogen synthase, a plethora of diﬀerent substrates has been
identiﬁed in all cellular compartments, that is, metabolic
proteins [3], cytoskeletal proteins [4], and transduction [5]
and transcription factors [6]( s e eTable 1).
In neuronal development, GSK-3 has been reported to
control morphogenesis and axonal polarity [7], synaptogen-
esis [8], and survival [9, 10]. In addition, GSK-3 dysfunction
has been associated with brain pathological conditions, such
as Alzheimer’s disease (AD) [11, 12] or prion neurotoxicity
[13]. Thus, the deep knowledge of the role of both GSK-3
isoforms in brain metabolism will allow us to understand
their contribution to neurodegenerative processes.
GSK-3 unique position in modulating the function of a
diverse series of proteins in combination with its association
with a wide variety of human disorders has attracted
signiﬁcant attention to the protein both as a therapeutic
target and as a means to understand the molecular bases of
these disorders. Furthermore, GSK-3 appears to be a cellu-
lar nexus, integrating several signalling systems, including
numerous second messengers and a wide selection of cellular
stimulants.
2.GSK-3Structure
GSK-3 has been highly conserved during evolution, and
homolog genes have been identiﬁed in virtually every
eukaryotic genome investigated, including species, such
as Dictyostelium discoideum, Xenopus laevis,o rDrosophila
melanogaster [14–16].Inmammals, GSK-3isencodedbytwo
genes known as gsk-3α and gsk-3β [17, 18]e n c o d i n gG S K -
3α (483 aa in humans) and GSK-3β (433 aa) proteins with
apparent molecular masses of 51 and 47kDa, respectively.
Both isoforms are almost identical (98%) within their ATP
bindingpocketbutdiﬀerattheirN-andC-terminaldomains
[19]. A neuron-speciﬁc splicing isoform (β2) having an2 International Journal of Alzheimer’s Disease
Table 1: GSK-3 substrates.
Metabolic proteins Structural proteins Transcription
factors
Glycogen synthase Tau AP-1
ATP cytrate lyase MAP1B β-catenin
PKA MAP2 CREB
PDH NCAM C/EBP
Acetyl-CoA
carboxylase Neuroﬁlaments Myc
PP1 CRMP2 NFκB
PP2A inhibitor Dynein NFAT
PP2A Dynamin-like
protein GR
Cyclin D1 MBP HSF-1
eIF2B APC Notch
NGF receptor Kinesin light chain p53
Axin HIF-1
APP
Bax
VDAC
Hexokinase
Presenilin
LRP5/6
Substrate
S/T XXXS/T
GSK-3
P P
GSK3 Selectivity
insertion of 13 aa within the substrate-binding domain has
alsobeendescribed[20].Mammalian GSK-3αandβ areeach
widely expressed although some tissues show preferential
levels of some of the two proteins. Neither gene appears to
be acutely regulated at the transcriptional level.
Crystallographic studies have revealed the three-
dimensional structure of GSK-3β [21, 22]. Its overall
shape is shared by all kinases, with a small N-terminal
lobe mostly consisting of β-sheets and a large C-terminal
lobe essentially formed of α-helices [23]. The ATP binding
pocket is located between the two lobes and although,
is well conserved among kinases [24], it is possible to
obtain selective inhibitors by taking advantage of the small
diﬀerences that exist between the diﬀerent kinases. Current
availability of crystal structures of complexes of GSK-3β
with a variety of ligands, together with molecular modelling
approaches, provides the necessary clues for enhancing
selectivity towards GSK-3 [22].
Some GSK-3 substrates do not require a very speciﬁc
sequence, but rather a previous (primed) phosphorylation
by a priming kinase on a Ser or Thr residue located four
aminoacids, C-terminal to the Ser or Thr residue to be
modiﬁedbyGSK-3(seebelowforregulationthroughprimed
phosphorylation). The crystal structure of human GSK-3β
has provided a model for the binding of prephosphorylated
substrates to the kinase. According to it, primed Ser/Thr is
recognized by a positively charged binding pocket formed
by residues Arg96, Arg180, and Lys205 that facilitates the
binding ofthephosphate groupofprimed substrates. GSK3β
uses thephosphorylated serine or threonineat position+4 of
thesubstratetoalignofthetwodomainsforoptimalcatalytic
activity [21, 22].
Furthermore, crystal structures of GSK-3β complexes
with interacting proteins FRAT/GBP and axin have allowed
deﬁning the molecular basis for those interactions, which
play critical role in some signalling pathways (see below
for regulation through protein complex formation). These
studiesconﬁrmthepartialoverlapofthebindingsitesofaxin
and FRAT1/GBP predicted from genetic and biochemical
studies [2, 25] but reveal signiﬁcant diﬀerences in the
detailed interactions and identify key residues mediating the
diﬀerential interaction with both proteins. This ability of
GSK-3β to bind two diﬀerent proteins with high speciﬁcity
via the same binding site is mediated by the conformational
plasticity of the 285–299 loop, while some residues in this
versatile binding site are involved in interactions with both
axin and FRAT; others are involved uniquely with one or the
other [26].
3.HowIsGSK-3ActivityControlled?
As already mentioned above, one of the main characteristics
of GSK-3 is that its activity is high in resting, unstimulated
cells while regulated by extracellular signals that typically
induce a rapid and reversible decrease in enzymatic activity.
Glycogen synthase kinase-3 is a dual speciﬁcity kinase
diﬀerentially regulated by tyrosine and serine/threonine
phosphorylation [27]. And for many years, it was believed
to be a constitutively active kinase; however, it has become
apparent that the activity of GSK-3 may be regulated by a
variety of means. In fact, control of GSK-3 activity occurs by
complex mechanisms that are each dependent upon speciﬁc
signalling pathways. Thus, theregulatory mechanisms can be
classiﬁed as follow.
3.1. Regulation by Phosphorylation. The ﬁrst regulatory
mechanism described of GSK-3 activity involved the phos-
phorylation of speciﬁc residues of GSK-3 by other kinases,
and more recently through autophosphorylation [17, 28].
Four diﬀerent regions and residues have been described
in the GSK-3 molecule. The ﬁrst one corresponds with a
serine residue at positions 21 in GSK-3α and 9 in GSK-3β.I t
hasbeenclearlyestablishedthatphosphorylationofserine21
or 9 correlates with the inhibition of its kinase activity [29–
31]. Many protein kinases are capable of phosphorylating
GSK-3 at this residue, such as Akt, ILK, PKA, and p90Rsk
[32, 33], and many physiological situations of inhibition
of GSK-3 correlate with serine phosphorylation, such as
Insulin/IGF1, NGF, or estradiol treatments, not only in
neurons [34].
Additionally, two other regulatory sites have been
described. One is the threonine 43, present only in the
isoform GSK-3β, which may be phosphorylated by Erk [35].International Journal of Alzheimer’s Disease 3
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This phosphorylation correlated with GSK-3 inhibition.
Second, serine 389 and threonine 390 present in GSK-3β
have been shown to be phosphorylated by p38 MAPK [36].
In both cases, the data suggested that this phosphorylation
may increase the capacity of Ser-9 to be phosphorylated
rather than promote a direct inhibition (see Figure 1).
In contrast, tyrosine phosphorylation present in posi-
tions 279 in GSK-3α or 216 in GSK-3β, appears to correlate
with an increase of its kinase activity [37]. Diﬀerent candi-
dates such as Pyk-2 and Fyn kinases have been reported to
be able to phosphorylate GSK-3 in vitro on tyrosine. In addi-
tion, MEK1/2 has been showed to have this capacity only in
ﬁbroblasts [38, 39]. This datacontrast with those reported in
Dictyostelium discoideum where there is compelling evidence
indicating that ZAK 1 is responsible for generating tyrosine
phosphorylationin GSK-3[14, 40].However, no homologue
of such kinase has been found in mammals.
More recently, an alternative hypothesis has been pro-
posed for the regulation of GSK-3 tyrosine phosphoryla-
tion. This hypothesis suggests that in mammalian systems
phosphotyrosine in GSK-3 corresponds to an intramolec-
ular autophosphorylation event and may be regulated
by Hsp90 [41]. Molecular dynamics and crystallographic
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studies clearly suggest that Tyr216 renders the kinase active
through interactions with Arg220 and Arg223, stabilizing
the activation loop and allowing full substrate accessibility
[42, 43]. However, this hypothesis still lacks a cellular
demonstration.
However, ourdata indicated that not all pharmacological
inhibitors of GSK-3 decrease the level of phosphotyrosine.
Therefore, lithium chloride inhibits GSK-3 activity, but this
inhibition does not alter its pTyr content [44]. Moreover, in
neuronal cells, tyrosine phosphorylation of residue 216 or
279 increased following exposure to LPA [37] and evenupon
exposure of neurons to β-amyloid or PrP [13, 45, 46]i na
clear correlation with an increase in GSK-3 activity. In addi-
tion, in many neuronal cells, the pharmacological inhibition
of tyrosine phosphatases with ortho-vanadate increases the
basal level of GSK-3-pTyr [44]. Thus, considering all these
data, in addition to this tantalizing autoregulatory system
proposed, we hypothesized that some as-yet-unidentiﬁed
tyrosine kinases and phosphatases may also regulate this
kinase (see Figure 2).
3.2. Regulation by Protein Complex Association. One regula-
tory mechanism that is still not fully understood involves the
interaction of the GSK-3 with structural proteins (scaﬀold
proteins). It is well known that GSK-3 contributes to a
multiprotein complex formed by axin and adenomatous
polyposis coli (APC), among others (for review see, i.e.,
[47]). This protein complex is the core of canonical Wnt
signalling (see below). Indeed, in the absence of ligand,
GSK-3 is able to phosphorylate β-catenin for targeting it
for proteasome degradation [48]. More recently, some data
suggests that this complex may be speciﬁc for GSK-3β2
isoform [49],which opens the possibility ofa deeper analysis
of “speciﬁc functions of GSK-3 isoforms.”
Another system of protein-kinase interaction was
denoted as GSK-3-binding protein (GBP or FRAT) [25, 50].4 International Journal of Alzheimer’s Disease
Three diﬀerent FRATs have been cloned and characterized;
however, their mechanism of action is not well understood.
FRAT1 appears to act as an inhibitory system [51], whereas
FRAT2 appears to preferentially increase GSK-3-mediated
phosphorylation in some residues [52]. Surprisingly, recent
data demonstrated that FRAT is dispensable because the
triple FRAT-knockout mouse lacks any major defect in brain
development [53]. All these data indicated that the precise
role of FRAT in GSK-3 regulation is still to be deﬁned.
Using the binding site on GSK-3 for FRAT/GBP, a GSK-
3-interacting protein symbolized by GSKIP has been cloned
and characterized. GSKIP can block phosphorylation of
diﬀerent substrates and functions as a negative regulator of
GSK-3 beta [54].
3.3. Regulation by Priming/Substrate Speciﬁcity. As previ-
ously mentioned, the speciﬁcity of many kinases is governed
by a consensus sequence of aminoacids sequence. However,
as almost general rule, GSK-3 substrates do not require a
very speciﬁc sequence, but a previous (primed) phospho-
rylation residue modiﬁed by a priming kinase located four
aminoacids, C-terminal, to the Ser or Thr residue to be
modiﬁed by GSK-3. The crystal structure of human GSK-
3β provides a model for the binding of prephosphorylated
substrates to the kinase (PDB ID are 1I09 [22] and 1H8F
[21]). According to it, primed Ser/Thr is recognized by
a positively charged binding pocket formed by residues
Arg96, Arg180, and Lys205 that facilitates the binding of the
phosphate group of primed substrates.
Some “priming kinases” have been identiﬁed, such as
cdk-5 [55–57], PAR-1 [58], casein kinase I [59], PK-C [60],
orPK-A[57]. However,it is not clearso far whether a second
set of “nonprimed” substrates may deﬁne a diﬀerent group
of functions [61]. In addition, diﬀerent glycogen synthase
kinase-3 isoforms appear to exhibit distinct substrate pref-
erence in the brain [62].
3.4. Regulation by Subcellular Localization. In developmental
brain, the presence of GSK-3 was high at E18 and peaked
on P8, decreasing after that period [63]. In addition, this
report showed that the developmental proﬁle of GSK-3α
and GSK-3β is diﬀerent, having β downregulated after birth
which suggested a diﬀerential role in neuronal development.
However, the putative diﬀerential role of each isoform has
been explored in few reports, that is, [7]. It is important to
indicatethata portion ofGSK-3,mostlyβ, hasbeenreported
tobeassociated in thegrowthcone.This GSK-3pool appears
to respond rapidly, being modiﬁed by phosphorylation
and/or relocated in the growth cone by external signals such
as Semaphorins [64]o rN G F[ 65].
GSK-3 activity is also dependent on its subcellular
localization; some data illustrated the presence of GSK-3α
and β in many neuronal compartments and in primary
neurons, either in axon, dendrite, or in nucleus [66, 67]. In
addition, GSK-3 has been found in the cytoplasm, nucleus
and the mitochondria [18]. Considering the list of GSK-
3 substrates reported, it is evident that most of its activity
should occur in the cytoplasm and in the nucleus, while we
have less information about GSK-3 potential targets in the
mitochondria. Recent data suggested that proteins such as
Mcl-1 [68] and hexokinase [69]m a yb er e g u l a t e db yG S K -
3 activity. It has been suggested that nuclear GSK-3 may be
involved in phosphorylation of many transcription factors
such as cyclin D1, β-catenin, HSF-1, NFAT, and cAMP-
response element-binding protein, among others (Table 1),
for review see [28, 70, 71]. Also, it has been proposed that
GSK-3 in the nucleus may have a role in alternative splic-
ing [72]. In addition, proapoptotic stimuli induce nuclear
accumulation of GSK-3β [73]; however, this hypothesis has
been not established in other neuronal death paradigms (D.
Simon, unpublished observations).
Further insight into GSK-3 regulation has been gained
very recently by revealing an essential role of multivesicular
endosomes in the Wnt signalling pathway. A combination of
protease protection assays, detergent permeabilization, and
cryoimmunoelectron microscopy demonstrated that Wnt
activationoftheFrizzledand LRP6receptorstriggersseques-
tration of GSK-3 into these membrane-bounded organelles,
leading to decreased GSK-3 levels in the cytosol [74]. This
process seems to require β-catenin, forming a feed-forward
loop by facilitating GSK-3 sequestration.
3.5. Regulation by Proteolytic Cleavage. An e wm e c h a n i s m
of GSK-3 regulation has been recently proposed. This reg-
ulation involves the removal by calpain of a fragment from
the N-terminal region of GSK-3, including the regulatory
serines 9/21.After removal of that fragment, GSK-3 becomes
activated [75]. The same study showed that both isoforms
α and β are cleaved by calpain, although with diﬀerent sus-
ceptibility. Moreover, GSK-3 truncation has been observed
in human and mouse postmortem brain tissue [76]. It is
noteworthy to consider that a similar mechanism has been
described forβ-catenin in hippocampal neurons, where after
NMDA-receptor-dependent activation, calpain induced the
cleavageofβ-cateninattheNterminus,generatingstableand
truncated forms which maintain its transcriptional capacity
[77].Likewise,GSK-3truncationismediatedbyextracellular
calcium and can be inhibited by memantine [76], an NMDA
antagonist used for the treatment of Alzheimer’s disease.
Interestingly, GSK-3β h a sa l s ob e e nr e c e n t l ys h o w nt ob e
cleaved at the N-terminus (and subsequently activated) by
matrix metalloproteinase-2 (MMP-2) in cardiomyoblasts
[78].
4.PathwaysControllingGSK-3
ActivityinNeurons
The regulation of GSK-3, as previously mentioned, is
an essential regulatory key controlling many physiological
processes in neurons. Many external signals may trigger
pathways that ﬁnally may activate or inhibit GSK-3 activity,
either transiently or in more sustained way. These “physio-
logical pathways” could be subdivided in two major clusters,
those that essentially have to inhibit GSK-3 activity, and
second, those that may, at least transiently, trigger GSK-3
activity.International Journal of Alzheimer’s Disease 5
4.1. Inhibitory Pathways. Among these pathways, the sig-
nalling triggered by Insulin or IGF-1 [19, 79, 80]a n d
NGF/BDNF/NT3 [81, 82] has similar features. These tyro-
sine kinase receptors initiated cytoplasm signals in which
the inhibition of GSK-3 activity is a common feature. It
is generally accepted that the kinase implicated in this
inhibition is PKB/Akt [29–31], even though kinases such
as PKA or ILK have also been implicated [32, 33]. In all
cases, phosphorylation on serine 21 and 9 (α and β,r e s p . )
represents the inhibition of the GSK3 kinase activity, as
previously mentioned.
The second well-documented pathway is Wnt/Wingless
signalling [83, 84]. This signalling has been widely studied,
and it has been shown to be essential in early embryonic
patterning, cell fate, cellular polarity, and cell movement in
both vertebrates and invertebrates [47, 85]. In many if not
a l lc e l ls y s t e m s ,t h ec a n o n i c a lW n tp a t h w a yi sf o r m e db ya
set of phylogenetically conserved proteins including the Wnt
receptor frizzled (fz), and a coreceptor LRP5/6; Dishevelled
(Dsh), and a scaﬀolding protein that activates a complex
formed by Axin/APC/GSK3-β/β-catenin [47, 85–88].
In this pathway, in the absence of ligand, GSK-3β phos-
phorylates β-catenin, among other proteins, this phosphory-
lationconstituting part ofa degradationsignal forβ-catenin.
However, in the presence of Wnt, the receptor complex
triggers a signal in which Dsh inhibits the activity of GSK-
3β by a mechanism not completely understood, so far. This
system appears to be speciﬁc for GSK-3β as no counterpart
has been described for GSK-3α to date; however, some GSK-
3 activity appears to be necessary for Wnt signalling [89, 90].
More recently, a bioinformatics-based screen for proteins
whose stability may be controlled by GSK-3 [91]h a sl e dt o
the identiﬁcation of a number of multiple Wnt signalling
target proteins, suggesting that this pathway controls a
broad range of cellular activities apart form β-catenin-
mediated transcriptional activation. Furthermore, GSK-3-
mediated Wnt signalling seems to regulate the turnover
of many cellular proteins [74, 91], indicating that GSK-
3 phosphorylation-dependent protein degradation may be
a widespread cellular mechanism to regulate a variety of
cellular processes in response to extracellular signals [71].
Functional segregation of the insulin/growth factor
and Wnt roles requires either that there be no exchange
between the subsets of the cellular GSK-3β pool committed
to each role, or that the recruitment of GSK-3β to the
axin-APC complex can reverse or override inhibitory Ser9
phosphorylation present in a recruited GSK-3β molecule.
Phosphatases capable of removing extant Ser9 phosphory-
lation are certainly known to be associated with the axin-
APC complex [92, 93]. Alternatively, the very substantial
enhancement in activity towards β-catenin aﬀorded by the
axin “scaﬀolding” may simply allow a primed β-catenin
substratetooutcompeteapSer9-GSK-3βN-terminalpeptide
for access to the substrate-binding site [26].
Estrogens regulate many physiological processes and
fulﬁl a wide range of functions during development and
diﬀerentiation in mammals of both sexes. The actions of
estrogens are mediated by estrogen receptors and have been
classiﬁed as either “genomic actions” or “nongenomic, rapid
actions.” The genomic actions are based on the capacity
of the estrogen receptors (ERs) to modulate transcriptional
activity either directly or through coactivators or corepres-
sors, that is, [94, 95].
More recently, it has been shown that in addition to
its direct transcriptional activity, estrogen receptors activate
a set of cytoplasm signals in a similar manner to some
growth factors. Hence, it has been reported that estradiol
acts synergistically with IGF-1 in the brain or in neurons,
activating the PI3K/Akt pathway [34, 96, 97]. We described
that the addition of estradiol increases the serine phospho-
rylation of GSK-3. This inhibitory phosphorylation is time-
and concentration dependent, and an antagonist of estradiol
prevents this event. The kinase responsible is sensitive to
the inhibition of the PI3K pathway, and for this reason,
it seems that the best candidate would be Akt [98, 99]. A
more detailed analysis of these new signals will give us clear
evidencewhether this pathwayis completelyconvergentwith
those using PI3K/Akt/GSK3,as previously mentioned.
4.2. Activation Pathways. In neurons, LPA has been shown
to induce neurite retraction and the rounding up of neu-
roblastoma cell lines [100]. In some primary neurons, it
also promotes growth cone collapse and neurite retraction
[37, 101]. This bioactive lipid acts as a growth factor through
speciﬁc seven transmembrane domain receptors, denoted
as lpa 1–4 [102, 103]. We described that GSK3 activity
was increased after LPA treatment in diverse neuronal
cells of diﬀerent species in correlation with the neurite
retraction process [104, 105]. This activation correlated with
an increase in GSK3-PTyr and may be downstream Gα12
or Gα13 [101, 105, 106]. The previous inhibition of GSK3
activity prevents, at least in part, the growth cone collapse
response. Similarly, it has been reported that three diﬀerent
GSK-3 antagonists (LiCl, SB-216763, and SB-415286) can
inhibit the growth cone collapse response induced by Sema
3A [64].
However, the exact mechanism of how this activation of
G S K 3o c c u r si sn o tk n o w n ,s of a r .M a n yr e p o r t si n d i c a t e
that in Dictyostelium discoideum GSK-3 activity may increase
in response to cAMP binding to a heptahelical G-protein-
coupled receptor. In this system, a tyrosine kinase and a
tyrosine phosphatase have been described as regulators of
GSK-3 activity [14, 40], but similar kinase and phosphatase
have not been found in mammals.
Furthermore, it has been reported that Reelinand Netrin
increased GSK-3 activity, similar to what LPA did. This
Netrin or Reelin-dependent GSK-3 activation seems not
to be a particular characteristic of the cell line or neuron
used but rather a more general physiological process [107–
109]. Indeed, even in situations where the ﬁnal balance is
an inhibition of GSK-3 kinase activity, such as following
the addition of IGF1/Insulin or after estradiol addition, a
transient activation of GSK-3 could be observed [34, 38]. All
these data suggest that the upregulation and downregulation
of this kinase is more complex than might initially have been
considered.6 International Journal of Alzheimer’s Disease
5.PathologicalActivationofGSK-3
Deregulation of GSK-3 has been linked to a wide range of
human pathological conditions including type II diabetes,
muscle wasting, cancer and neurological disorders such as
bipolar disorder, schizophrenia, depression, stroke, sleep
disorders, and Alzheimer’s disease (AD), among others, for
ar e v i e ws e e[ 110].
Lithium and valproic acid are mood stabilizers widely
used in the chronic treatment of bipolar disorders. Lithium
ions directly inhibit GSK-3 [111], most likely by competing
with magnesium [112], while valproic acid is able to inhibit
GSK-3 activity in relevant therapeutic concentrations in
human neuroblastoma cells [113]a l t h o u g hin vivo direct
inhibition of GSK-3 by valproic acid remains a matter of
debate [114]. The precise mechanism of action by which
lithium exerts its therapeutic eﬀects is not known, but it is
conceivable that the acute eﬀects on GSK-3 result in changes
in gene regulation and cellular changes which could aﬀect
the neuronal plasticity over time [115]. Actually, lithium
is also an inhibitor of several phosphomonoesterases [116]
and phosphoglucomutases [117], but the fact that GSK-3
has been shown to be signiﬁcantly inhibited at therapeutic
lithium concentrations [118–120] suggests that at least a
signiﬁcant proportion of lithium’s therapeutic actions in
bipolar disorder results from the inhibition of GSK-3,
underlying its importance as a therapeutic target for this
disorder [121, 122].
Lymphocytes of patients with schizophrenia show
impaired GSK-3 protein levels and activity [123], whereas
GSK-3 has been reported to be reduced in the frontal
cortex of postmortem schizophrenic brains [124]. Since the
Wnt family of genes plays a central role in normal brain
development, it is possible that GSK-3 impairment may
lead to abnormal neuronal development. More recently, a
direct association has been shown between GSK-3 and the
N-terminalregionofdisrupted-in-schizophrenia-1 (DISC1),
a strong genetic risk factor associated with schizophrenia
[125]. Moreover, mounting evidence suggests that GSK-3
is a crucial node that mediates various cellular processes
that are controlled by multiple signalling molecules such
as DISC-1, PAR3, PAR6, and Wnt proteins that regulate
neurodevelopment [88].
Interestingly, increased levels of GSK-3 have also been
reported in postmortem analysis of brains from AD patients
compared to age-matched control samples [126], whereas
a spatial and temporal pattern of increased active GSK-
3β expression correlates with the progression of NFT and
neurodegeneration[127].Apart from being the major kinase
to phosphorylate tau both in vitro and in vivo [128], GSK-3
hasbeenrecentlyproposedasthelinkbetween thetwomajor
histopathological hallmarks of AD, the extracellular amyloid
plaques and the intracellular NFT [129, 130].
Exposure of primary neuronal cultures to Aβ induces
activation of GSK-3 [131], tau phosphorylation [132], and
cell death [133, 134], whereas blockade of GSK-3 expression
by antisense oligonucleotides or its activity by lithium
inhibits Aβ-induced toxicity [135, 136]. GSK-3 inhibition
per se decreases Aβ production in cells and in an animal
modelofamyloidosis[61,120],mostlikelythroughamecha-
nism involving inhibition of γ-secretase [137]. Furthermore,
amyloid precursor protein (APP) itself is a substrate for
GSK-3 in vitro and in vivo [138]. Finally, modulation of the
GSK-3 signalling pathway by chronic lithium treatment of
transgenic animals mightalsohaveneuroprotectiveeﬀectsby
regulating APP maturation and processing [138].
In tauopathies such as frontotemporal dementia with
Parkinsonism (FTDP) linked to chromosome 17, the pres-
ence of some mutations in tau protein correlates with the
onset of the disease [139, 140]. Treatment of transgenic mice
overexpressing mutant human tau (P301L, 4RON), with the
GSK-3 inhibitor lithium, has been shown to signiﬁcantly
decrease the levels of tau phosphorylation and signiﬁcantly
reducethelevelsofaggregated, insolubletau.Administration
in this model of a second GSK-3 inhibitor, AR-A014418,also
correlated with reduced insoluble tau levels, supporting the
notionthatlithiumexertsitseﬀectthroughGSK-3inhibition
[23]. More recently, chronic lithium administration has also
been shown to reduce tau phosphorylation in the 3xTg-AD
mice [141], but did not signiﬁcantly alter the amyloid load.
An increase in GSK-3 activity has also been shown to
coincide with cell death following middle cerebral artery
occlusion in mice which results in cortical infarcts [142],
and a reduction in infarct volume with the GSK-3 inhibitor
lithiumwasdemonstrated [143], indicatingthat GSK-3inhi-
bition may be beneﬁcial in stroke. In fact, pharmacological
inhibition of GSK-3 reduced infarct volume and improved
behaviour in a focal cerebral ischemia model [144].
6.GSK-3asa TherapeuticTarget
Besides deregulation of its activity in neurodegenerative
processes, mounting evidence further suggests a potential
role for GSK-3 as a therapeutic target in a range or other
pathologies, including pancreatic cancer [145], parenchymal
renal diseases [146], and HIV-1-associated dementia [147],
among others.
The recent discovery that glycogen synthase kinase-3
(GSK-3) promotes inﬂammation through nuclear factor
kappa B( N F κB) has revealed new functions on regulating
inﬂammatory processes [148]. Furthermore, GSK-3 inhi-
bition provides protection from inﬂammatory conditions
in diﬀerent animal model [149], suggesting that GSK-3
inhibitors may have multiple eﬀects inﬂuencing these con-
ditions.
Finally, recent developments suggest an active role of
GSK-3β in various human cancers, although its role in
tumourigenesis and cancer progression remains controver-
sial. It may function as a “tumour suppressor” for certain
types of tumours, whereas it seems to promote growth
and development for some others. Deregulation of GSK-
3β has been shown to promote gastrointestinal, pancreatic,
and liver cancers and glioblastomas. Furthermore, GSK-3β
inhibition attenuates cell survival and proliferation, induces
cell senescence and apoptosis, and sensitizes tumour cells to
chemotherapeutic agents [150] and ionizing radiation [151].
Nevertheless, an attractive target for a variety of humanInternational Journal of Alzheimer’s Disease 7
diseases, its therapeutic potential on tumourigenesis, and
cancer chemotherapy still needs to be carefully evaluated
[152].
The close involvement of GSK-3 activity in diﬀerent
human pathologies has sparked intense eﬀorts in developing
inhibitors as therapeutic agents. Thus, the discovery of small
molecule GSK-3 inhibitors in the last few years has not only
attracted signiﬁcant attention to the protein as a therapeutic
target but also has provided a means to further understand
the physiological functions of GSK-3 and to gain further
insight into the molecular basis of those disorders.
In fact, at least one small molecule GSK-3 inhibitor
program has made it to the clinic [153]. Tideglusib (NP-
12) is a synthetic small molecule form the TDZD chemical
class [110] which is currently in phase II development for
two CNS indications: Alzheimer’s disease and progressive
supranuclear palsy (PSP), a tauopathy [154].
7.Conclusion
Three decades after its discovery as a protein kinase involved
inglycogenmetabolism, GSK-3wasrevealedasa keyenzyme
in regulating many critical cellular processes, providing a
linkbetweenmany diﬀerentsubstrates andvarious signalling
pathways as well as gene expression. Modulation of its
activity has also turned out to be much more complex than
originally thought, as evident from what has been reviewed
here. Furthermore, its role in a variety of highly relevant
human pathological conditions has drawn signiﬁcant atten-
tion to this enzyme as a potential therapeutic target, and the
recent developmentof speciﬁc inhibitors has granted us new
tools to dissect out its molecular and physiological functions
while providing novel therapeutic agents. Taken all together,
the next few years will certainly bring us further insights into
the cellular functions of this fascinating enzyme.
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